Genzyme 2Q Revenues: $1.2 billion (+25%) 2Q Earnings: $69.6 million (-17%) YTD Revenues: $2.3 billion (+25%) YTD Earnings: $214.8 million (-11%) Comments: Myozyme sales were up 65% in the quarter to $77.2 million. The company is still awaiting approval of its Myozyme 2000L-scale facility in the U.S.; the FDA is expected to discuss the BLA in October. Cerezyme sales were up 13% to $319.4 million. Sales of Fabrazyme were up 21% to $126.6 million. Sales of Aldurazyme were up 33% to $...